Gene-Guided cancer therapy put to the test in 742 patients

NCT ID NCT01771458

Completed Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether choosing cancer drugs based on the genetic makeup of a patient's tumor works better than standard treatment. It included 742 adults with advanced solid tumors that had stopped responding to usual therapies. Patients were randomly assigned to receive either a targeted therapy matched to their tumor's molecular profile or conventional treatment chosen by their doctor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECCURENT/METASTATIC SOLID TUMOR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECCURENT/METASTATIC SOLID TUMOR DISEASE

Contacts and locations

Locations

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54500, France
Centre Leon Berard

Lyon, 69373, France
Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc

Dijon, 21079, France
Insitut Curie

Paris, 75248, France
Institut Claudius Régaud

Toulouse, 31052, France
Institut Curie Hopital Rene Huguenin

Saint-Cloud, 92210, France
Institut Paoli Calmettes

Marseille, 13009, France
Institut de cancérologie de l'Ouest Centre René Gauducheau

Saint-Herblain, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.